OpenLB
Open Library of Bioscience
Advanced Search
BioMed research international
2021;2021 9929805.

Involvement of GABA Receptors in the Anxiolytic-Like Effect of Hydroxycitronellal.

Jéssica C Andrade, Álefe B Monteiro, Humberto H N Andrade, Thallita K S N Gonzaga, Pablo R Silva, Danielle N Alves, Ricardo D Castro, Mayara S Maia, Marcus T Scotti, Damião P Sousa, Reinaldo N Almeida
Author Information
  1. Jéssica C Andrade: Psychopharmacology Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, Campus I, 58051-085, Via Ipê Amarelo/SN, João Pessoa, Paraíba, Brazil. ORCID
  2. Álefe B Monteiro: Psychopharmacology Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, Campus I, 58051-085, Via Ipê Amarelo/SN, João Pessoa, Paraíba, Brazil. ORCID
  3. Humberto H N Andrade: Psychopharmacology Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, Campus I, 58051-085, Via Ipê Amarelo/SN, João Pessoa, Paraíba, Brazil. ORCID
  4. Thallita K S N Gonzaga: Psychopharmacology Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, Campus I, 58051-085, Via Ipê Amarelo/SN, João Pessoa, Paraíba, Brazil. ORCID
  5. Pablo R Silva: Psychopharmacology Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, Campus I, 58051-085, Via Ipê Amarelo/SN, João Pessoa, Paraíba, Brazil. ORCID
  6. Danielle N Alves: Department of Clinic and Social Dentistry, Center for Health Sciences, Federal University of Paraiba, Campus I, João Pessoa, PB, Brazil. ORCID
  7. Ricardo D Castro: Department of Clinic and Social Dentistry, Center for Health Sciences, Federal University of Paraiba, Campus I, João Pessoa, PB, Brazil. ORCID
  8. Mayara S Maia: Cheminformatics Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, Campus I, 58051-900, Via Ipê Amarelo/SN, João Pessoa, Paraíba, Brazil. ORCID
  9. Marcus T Scotti: Cheminformatics Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, Campus I, 58051-900, Via Ipê Amarelo/SN, João Pessoa, Paraíba, Brazil. ORCID
  10. Damião P Sousa: Pharmaceutical Chemistry Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa, Brazil. ORCID
  11. Reinaldo N Almeida: Psychopharmacology Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, Campus I, 58051-085, Via Ipê Amarelo/SN, João Pessoa, Paraíba, Brazil. ORCID
PMID: 34222487 DOI: 10.1155/2021/9929805

Abstract

Hydroxycitronellal (HC) is a monoterpene present in essential oils of aromatic plants of different species, obtained from semisynthesis of citronellal, and is widely used as a fragrance in cosmetics. The objective of this work was to evaluate the possible anxiolytic-like activity of HC and its possible mechanism of action using and methodologies. Swiss male mice () were treated with HC (12.5, 25, and 50 mg/kg, i.p.) and subjected to the rota rod, elevated plus maze, and open field tests. No significant impairments were observed in the rota rod tests for the motor activity of the animals treated with HC at 12.5, 25, and 50 mg/kg, i.p., indicating no myo-relaxing or sedative effects. In the elevated plus maze, HC (in the three doses) induced significant increases in the percentage of entries (respectively, 34.8%, 33.8%, and 38.6%) and in the length of stay (respectively, 49.9%, 56.1%, and 57.0%) in the open arms of the EPM, as well as the number of crossings in the open field tests. The mechanism of action of the compound's anxiolytic-like activity can be attributed to the involvement of GABA receptors, and this interaction was observed in and studies. For HC, the results suggest anxiolytic-like effects, possibly via modulation of the GABAergic system. The use of natural products to treat anxiety can become an alternative to existing synthetic products.

References

  1. J Comput Chem. 2004 Oct;25(13):1605-12 [PMID: 15264254]
  2. Fundam Clin Pharmacol. 2018 Oct;32(5):507-515 [PMID: 29577374]
  3. Bioorg Med Chem. 2018 Nov 1;26(20):5388-5396 [PMID: 30293795]
  4. Neurosci Biobehav Rev. 2001 May;25(3):235-60 [PMID: 11378179]
  5. Biomolecules. 2019 Dec 06;9(12): [PMID: 31817682]
  6. PLoS One. 2013;8(1):e52323 [PMID: 23308109]
  7. Structure. 2013 Sep 3;21(9):1485-91 [PMID: 24010707]
  8. Braz J Med Biol Res. 2012 May;45(5):436-43 [PMID: 22473320]
  9. Molecules. 2015 Oct 14;20(10):18620-60 [PMID: 26473822]
  10. Pharmacol Biochem Behav. 2012 Dec;103(2):220-9 [PMID: 22960127]
  11. Oxid Med Cell Longev. 2019 Mar 31;2019:1346878 [PMID: 31049124]
  12. Phytomedicine. 2010 Jul;17(8-9):679-83 [PMID: 19962290]
  13. Vet Anaesth Analg. 2014 Nov;41(6):621-9 [PMID: 24628858]
  14. Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):605-9 [PMID: 20211673]
  15. J Chem Theory Comput. 2011 Dec 13;7(12):4026-37 [PMID: 26598349]
  16. J Biomed Biotechnol. 2011;2011:678673 [PMID: 21660140]
  17. Molecules. 2011 Mar 07;16(3):2233-52 [PMID: 21383660]
  18. Brain Res. 2007 Sep 12;1169:87-97 [PMID: 17692295]
  19. Psychother Psychosom. 2020;89(5):274-282 [PMID: 32615566]
  20. Brain Res. 2012 Apr 11;1448:56-62 [PMID: 22364736]
  21. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):54-61 [PMID: 17761379]
  22. Eur J Pharm Sci. 2013 Mar 12;48(4-5):689-97 [PMID: 23305993]
  23. Pharmacol Biochem Behav. 1986 Mar;24(3):525-9 [PMID: 2871560]
  24. Braz J Psychiatry. 2013;35 Suppl 2:S101-11 [PMID: 24271222]
  25. Phys Med Rehabil Clin N Am. 2020 May;31(2):255-264 [PMID: 32279728]
  26. Curr Opin Neurobiol. 2011 Dec;21(6):842-8 [PMID: 21605970]
  27. Pharmacol Biochem Behav. 2004 Feb;77(2):361-4 [PMID: 14751465]
  28. J Am Pharm Assoc Am Pharm Assoc. 1957 Mar;46(3):208-9 [PMID: 13502156]
  29. Biomed Pharmacother. 2018 Jul;103:546-552 [PMID: 29677541]
  30. Eur J Med Chem. 2018 May 10;151:199-213 [PMID: 29614417]
  31. Biomed Pharmacother. 2017 Dec;96:320-327 [PMID: 29017144]
  32. Basic Clin Pharmacol Toxicol. 2017 Jan;120(1):22-29 [PMID: 27277137]
  33. Sci Rep. 2017 Mar 03;7:42717 [PMID: 28256516]
  34. Evid Based Complement Alternat Med. 2017;2017:7217619 [PMID: 29234424]
  35. Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26 [PMID: 11259830]
  36. Exp Neurobiol. 2019 Oct 31;28(5):593-601 [PMID: 31698551]
  37. Braz J Med Biol Res. 2016 Jan;49(1):e4872 [PMID: 26628396]
  38. Pharm Biol. 2010 Apr;48(4):411-6 [PMID: 20645719]
  39. Phytomedicine. 2001 Jul;8(4):310-22 [PMID: 11515723]
  40. J Chem Theory Comput. 2017 Apr 11;13(4):1518-1524 [PMID: 28267328]
  41. Anim Behav. 1973 May;21(2):205-35 [PMID: 4578750]
  42. Nat Prod Commun. 2010 Dec;5(12):1847-51 [PMID: 21299105]
  43. Molecules. 2018 Oct 19;23(10): [PMID: 30347669]
  44. Pharmacol Biochem Behav. 1996 May;54(1):21-30 [PMID: 8728535]
  45. Pharm Biol. 2013 Sep;51(9):1144-9 [PMID: 23795810]
  46. Int J Pharm. 2013 Aug 30;453(1):3-11 [PMID: 23124107]
  47. Phytomedicine. 2008 Aug;15(8):619-24 [PMID: 17976969]
  48. Molecules. 2019 Dec 06;24(24): [PMID: 31817569]
  49. Fed Proc. 1980 Oct;39(12):3039-42 [PMID: 6252065]
  50. Curr Top Med Chem. 2018;18(9):797-807 [PMID: 29875002]
  51. Phytomedicine. 2016 Aug 15;23(9):948-57 [PMID: 27387403]
  52. Life Sci. 2006 Mar 6;78(15):1720-5 [PMID: 16253279]
  53. Eur J Pharm Sci. 2011 Jul 17;43(4):260-9 [PMID: 21570465]
  54. Mol Neuropsychiatry. 2019 Apr;5(2):84-97 [PMID: 31192221]
  55. Contact Dermatitis. 1984 Jul;11(1):1-10 [PMID: 6378513]
  56. Pharmacol Toxicol. 1996 Sep;79(3):150-6 [PMID: 8884874]
  57. Biochem Pharmacol. 2005 Apr 1;69(7):1101-11 [PMID: 15763546]
  58. Biomed Res Int. 2019 May 7;2019:1639726 [PMID: 31205934]
  59. J Med Chem. 2006 Jun 1;49(11):3315-21 [PMID: 16722650]

MeSH Term

Animals
Anti-Anxiety Agents
Anxiety
Behavior, Animal
Computer Simulation
Hydrogen Bonding
Hypnotics and Sedatives
Length of Stay
Male
Maze Learning
Mice
Molecular Docking Simulation
Motor Activity
Receptors, GABA-A
Terpenes
Treatment Outcome

Chemicals

Anti-Anxiety Agents
Hypnotics and Sedatives
Receptors, GABA-A
Terpenes
hydroxycitronellal
Journal Article

Word Cloud

Created with Highcharts 10.0.0HCanxiolytic-likeactivityopentestsHydroxycitronellalpossiblemechanismactiontreated1252550 mg/kgiprotarodelevatedplusmazefieldsignificantobservedeffectsrespectively8%canGABAproductsmonoterpenepresentessentialoilsaromaticplantsdifferentspeciesobtainedsemisynthesiscitronellalwidelyusedfragrancecosmeticsobjectiveworkevaluateusingmethodologiesSwissmalemicesubjectedimpairmentsmotoranimalsindicatingmyo-relaxingsedativethreedosesinducedincreasespercentageentries3433386%lengthstay499%561%570%armsEPMwellnumbercrossingscompound'sattributedinvolvementreceptorsinteractionstudiesresultssuggestpossiblyviamodulationGABAergicsystemusenaturaltreatanxietybecomealternativeexistingsyntheticInvolvementReceptorsAnxiolytic-LikeEffect

Similar Articles

Cited By